SCHEMBL7303045

SCHEMBL7303045

O=C(O)C1CCN(C(=O)NCc2ccccc2)CC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.81
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
ALDH1A1 P00352 1/20 0.70
TSHR P16473 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.68
HRH3 Q9Y5N1 1/20 0.64
GLA P06280 2/20 0.64
L3MBTL1 Q9Y468 1/20 0.61
KDM4E B2RXH2 1/20 0.61
F2 P00734 1/20 0.60
PRSS1 P07477 1/20 0.60
GRIN2B Q13224 1/20 0.60
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841233 0.85 MEN1 (0.72) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL6813790 0.85 MEN1 (0.72) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL7312679 0.83 KMT2A (0.71) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL7312625 0.83 NPSR1 (0.68) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL5364705 0.82 MEN1 (0.77) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL4197501 0.82 KDM4E (0.69) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL5800630 0.82 KDM4E (0.69) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL14529027 0.81 HRH3 (0.80) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL22874743 0.81 KMT2A (0.67) NPSR1MEN1KMT2AALDH1A1TSHR
SCHEMBL5217325 0.81 KDM4E (0.68) NPSR1MEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981860-B2 Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-04-20 US disclosed
US-20190135733-A1 CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-05-09 US disclosed
EP-0520336-A2 Aldehyde derivatives and their use as calpain inhibitors FUJIREBIO Inc. (JP) 1992-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981860-B2 Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof CASP1, CASP14, CASP2 NPSR1 4548/4885MEN1 3391/4885KMT2A 4574/4885
US-20190135733-A1 CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF CASP1, CASP14, CASP2 NPSR1 4548/4885MEN1 3391/4885KMT2A 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.